Equity LifeStyle Properties, Inc. Announces Third Quarter 2026 Earnings Release And Conference Call

CHICAGO, Oct. 12, 2026 /PRNewswire/ -- Equity LifeStyle Properties, Inc. (NYSE: ELS) (referred to herein as the "Company," "we," "us," and "our") announced today that the Company's third quarter 2026 earnings will be released on Tuesday, October 20, 2026 after market close. The Company's executive management team will host a conference call and audio webcast on Wednesday, October 21, 2026 at 11:00 a.m. Eastern Time to discuss the Company's operating and financial results.

The live audio webcast and replay of the conference call will be available on our website at www.equitylifestyleproperties.com in the Investor Relations section under Events.

Research analysts and other interested parties who wish to participate in the conference call must register through this link at least fifteen minutes prior to the scheduled start of the call to receive the dial-in details.

This news release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When used, words such as "anticipate," "expect," "believe," "project," "intend," "may be" and "will be" and similar words or phrases, or the negative thereof, unless the context requires otherwise, are intended to identify forward-looking statements and may include, without limitation, information regarding our expectations, goals or intentions regarding the future, and the expected effect of our acquisitions. Forward-looking statements, by their nature, involve estimates, projections, goals, forecasts and assumptions and are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those expressed in a forward-looking statement due to a number of factors, which include, but are not limited to the following: (i) the mix of site usage within the portfolio; (ii) yield management on our short-term resort and marina sites; (iii) scheduled or implemented rate increases on community, resort and marina sites; (iv) scheduled or implemented rate increases in annual payments under membership subscriptions; (v) occupancy changes; (vi) our ability to attract and retain membership customers; (vii) change in customer demand regarding travel and outdoor vacation destinations; (viii) our ability to manage expenses in an inflationary environment, including the impact of changes in tariffs, as well as costs associated with supply chain disruptions; (ix) changes in debt service and interest rates; (x) our ability to integrate and operate recent acquisitions in accordance with our estimates; (xi) our ability to execute expansion/development opportunities in the face of changes impacting the supply chain or labor markets; (xii) completion of pending transactions in their entirety and on assumed schedule; (xiii) our ability to attract and retain property employees, particularly seasonal employees; (xiv) ongoing legal matters and related fees; (xv) costs to clean up and restore property operations and potential revenue losses following storms or other unplanned events; and (xvi) the potential impact of material weaknesses, if any, in our internal control over financial reporting.

For further information on these and other factors that could impact us and the statements contained herein, refer to our filings with the Securities and Exchange Commission, including the "Risk Factors" and "Forward-Looking Statements" sections in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q.

These forward-looking statements are based on management's present expectations and beliefs about future events. As with any projection or forecast, these statements are inherently susceptible to uncertainty and changes in circumstances. We are under no obligation to, and expressly disclaim any obligation to, update or alter our forward-looking statements whether as a result of such changes, new information, subsequent events or otherwise.

We are a fully integrated owner of lifestyle-oriented properties and own or have an interest in 453 properties located predominantly in the United States consisting of 173,559 sites as of June 30, 2026. We are a self-administered, self-managed, real estate investment trust with headquarters in Chicago.

SOURCE Equity Lifestyle Properties, Inc.

Share this article

RALEIGH, N.C., Oct. 12, 2026 /PRNewswire/ -- Bandwidth Inc. (NASDAQ: BAND), a leading global enterprise cloud communications company, today announced it will report its financial results for the third quarter ended September 30, 2026 before market open on Thursday, October 29, 2026.

Bandwidth will offer a live webcast of the conference call on the Investor Relations section of the company's website at https://investors.bandwidth.com, where a replay will also be available shortly following the completion of the event.

Conference call details:

Date: Thursday, October 29, 2026

Time: 8:00 a.m. Eastern Time

Dial-in number (domestic): 844-481-2707

Dial-in number (international): 412-317-0663

Replay information:

Following the completion of the call through Thursday, November 5, 2026, a replay will be available by dialing 855-669-9658 for the U.S. or 412-317-0088 for callers outside the U.S., and entering passcode 4828018.

About Bandwidth Inc.

Bandwidth Inc. (NASDAQ: BAND) is a global cloud communications company that helps enterprises deliver exceptional experiences through voice calling, text messaging and emergency services. Our solutions and our Communications Cloud, covering ~70 countries and 90 percent of global GDP, are trusted by all the leaders in unified communications and cloud contact centers–including Amazon Web Services (AWS), Cisco, Google, Microsoft, RingCentral, Zoom, Genesys and Five9–as well as Global 2000 enterprises and SaaS builders like Docusign, Uber and Yosi Health. As a founder of the cloud communications revolution, we are the first and only global Communications Platform-as-a-Service (CPaaS) to offer a unique combination of composableAPIs, AI capabilities, owner-operated network and broad regulatory experience. Our award-winning support teams help businesses around the world transform their communications every day.

SOURCE Bandwidth Inc.

Share this article

Greenbrier schedules fourth quarter fiscal 2026 earnings release and conference call

LAKE OSWEGO, Ore., Oct. 12, 2026 /PRNewswire/ -- The Greenbrier Companies, Inc. (NYSE:GBX) announced today it will be reporting its fourth quarter 2026 results after market on Monday, October 26, 2026. Shareholders and other interested parties are invited to listen to its financial results conference call at 2:00 p.m. PDT, live, via webcast or dial-in.

Listeners can access the webcast and earnings release at the Greenbrier website, www.gbrx.com. To register for or access the webcast, click on the announcement shown on the home page of the website. The webcast will be archived for 30 days.

Alternatively, dial-in numbers for the conference call are 1-888-317-6003 for domestic callers and 1-412-317-6061 for international callers; the passcode is "5771220". Please call in 10-15 minutes ahead of time to ensure proper connection.

About Greenbrier

Greenbrier, headquartered in Lake Oswego, Oregon, is a leading international supplier of equipment and services to global freight transportation markets. Through its wholly-owned subsidiaries and joint ventures, Greenbrier designs, builds and markets freight railcars in North America, Europe and Brazil. We are a leading provider of freight railcar wheel services, parts, maintenance and retrofitting services in North America through our maintenance services business unit. Greenbrier owns a lease fleet of approximately 20,600 railcars that originate primarily from Greenbrier's manufacturing operations. Greenbrier offers railcar management, regulatory compliance services and leasing services to railroads and other railcar owners in North America. Learn more about Greenbrier at www.gbrx.com.

SOURCE The Greenbrier Companies, Inc.

Share this article

News provided by

Choate's Air Conditioning, Heating, Plumbing, and Electrical

Oct 12, 2026, 16:11 ET

MEMPHIS, Tenn., Oct. 12, 2026 /PRNewswire/ -- Choate's Air Conditioning, Heating, Plumbing, and Electrical secured the 2026 Best of Memphis Award for Best HVAC Co., marking the company's fourth victory in this category over the last five years. The annual recognition, determined by the readers of the Memphis Flyer, highlights the service provider's sustained influence within the Mid-South market.

The win follows a period of consistent performance, where the company maintained a top-tier ranking for five consecutive years starting in 2022, including a second-place finish in 2025. Unlike industry certifications determined by internal metrics, the Memphis Flyer award reflects the direct preferences of the local community through a majority vote. The results indicate a high level of retention among multi-generational customer bases, a factor the company attributes to its legacy of technical reliability and community involvement.

Operational Growth and Legacy

The transition from a solo operation to a large-scale enterprise began in 1958 when Joe Choate launched the business with a single pick-up truck and a tool chest. The organization has since expanded into a regional leader under the leadership of Joe's son, Chris, and grandsons, Sol and Brian.

The enterprise now maintains a robust infrastructure to support its growing client base:

- 100 Field Vehicles: A large-scale fleet designed to provide comprehensive coverage and rapid response across the region.

- 140 Employees: A dedicated workforce that manages daily operations and specialized field services.

This recognition serves as a benchmark for integrity in an increasingly competitive market. By securing the majority vote, Choate's reinforces its standing as a primary choice for HVAC solutions in the Memphis metropolitan area, bridging the gap between mid-century service values and modern technical requirements.

SOURCE Choate's Air Conditioning, Heating, Plumbing, and Electrical

Share this article

Alaska Gear Company's Footwear Line Expands Beyond the Bunny Boot with New Ankle Deck Boot VBX

ANCHORAGE, Alaska, Oct. 12, 2026 /PRNewswire/ -- Alaska Gear Company (AKGC) is expanding its footwear line with the Ankle Deck Boot VBX, the first deck boot built with sealed vapor barrier insulation. The new ankle-height boot is constructed with AKGC's proprietary Vapor Barrier X (VBX) technology, the same waterproof insulation system behind the boots Alaskans have trusted for generations to keep their feet warm and dry when conditions turn cold and wet.

Cold, wet feet have always been more than a discomfort. During the World War II campaign to retake Attu, in Alaska's Aleutian Islands, Allied forces lost more soldiers to cold injury than to combat wounds. The U.S. Army's sealed insulated boot, developed in the years that followed, is credited with virtually eliminating frostbite and trench foot among troops in wet-cold conditions. The reason it worked is simple: once insulation gets wet, it loses much of its ability to hold heat, and feet can turn dangerously cold at temperatures as mild as 50°F.

AKGC built VBX around that same lesson: a rubber outer shell that seals out external water and snow, paired with a wool insulation layer that holds heat where it belongs. The boot is rated to an average of -45°F (ArCLO rating) based on lab testing, making it the warmest and most capable ankle deck boot available. The Ankle Deck Boot VBX takes that proven protection and brings it into a lower-profile, three-season boot for fall, winter, and spring, different from the deep-winter VBX MAX Bunny Boot. It's built for people who need full wet-cold protection on the docks or wherever the work takes them, while also functionable and comfortable as a daily driver for anyone facing cold, wet days around town.

Beyond VBX insulation, the Ankle Deck Boot VBX is finished with a fleece lining for everyday comfort, and a siped, non-marking outsole engineered with cold-resistant rubber. The sipes channel water away from the sole, so footing stays sure even when the ground doesn't.

"The Ankle Deck Boot VBX product is an answer to an authentic problem that our Alaskan community was having, and no other brand was solving. Our team at Alaska Gear Company knew that we had the opportunity to empower our coastal consumer to brave colder temperatures than they previously could utilizing our Vapor Barrier X technology in a waterproof deck boot package that is built to thrive in the harshest of conditions." - Henry Richenstein, Footwear Category Manager at Alaska Gear Company

The Ankle Deck Boot VBX is available now for $199 plus tax at AKGC's Anchorage and Fairbanks retail locations and online at www.alaskagearcompany.com.

AKGC's winter footwear line AKGC's winter footwear line is growing, too. The new NEO Bunny Boot arrives later this fall in Shale Black and Alpine Green. The Bunny Boot LITE adds two new colorways, Polar Purple and Brooks Brown, and the Bunny Boot MAX adds Alpine Green. Bunny Boots can be paired with colored, waxed reflective laces and gaiters for deep snow, and ice spikes for icy conditions work with both the Bunny Boots and the Ankle Deck Boot VBX.

About Alaska Gear Company

Alaska Gear Company (AKGC) is a locally Alaskan-owned outdoor gear brand, best known for the Bunny Boot, with retail stores in Anchorage and Fairbanks. The company is expanding distribution into the lower 48 United States and Canada.

Kate Rausch, [email protected]

SOURCE Alaska Gear Company

Share this article

Studies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings alone

FRIENDSWOOD, Texas, Oct. 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data from three studies evaluating its TissueCypher Barrett's Esophagus (BE) test will be presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and Postgraduate Course, taking place Oct. 9-14 in Nashville, Tennessee. The studies include two case reports and one multi-center study highlighting how TissueCypher can provide additional risk information beyond histopathology to support risk-aligned patient management decisions.

"Endoscopic biopsy findings do not always tell the whole story when it comes to a patient's risk of progression," said study author Virendra Joshi, M.D., FAGA, FACG, board-certified gastroenterologist and associate professor in the Division of Digestive Diseases in the Department of Medicine at Emory University School of Medicine in Atlanta. "The studies being presented at ACG demonstrate how TissueCypher can complement standard pathology by providing objective molecular risk information that helps guide surveillance and treatment decisions for patients with Barrett's esophagus, particularly when a patient's molecular risk suggests a different approach than their biopsy diagnosis alone would indicate."

BE is a precancerous condition associated with an increased risk of esophageal adenocarcinoma (EAC), yet biopsy findings alone do not always accurately reflect a patient's individual biological risk of progression. TissueCypher analyzes protein biomarkers and tissue architecture in routine endoscopic biopsy samples to provide an individualized five-year probability of progression to high-grade dysplasia (HGD) or EAC.

Study findings and presentation details are included below. All posters will be presented in Exhibit Halls A-D (Level 3) at Music City Center.

P3056: The Tissue Systems Pathology Test Enabled Detection of Missed Prevalent Dysplasia in a Presumed Clinically Low-Risk Patient With Non-Dysplastic Barrett's Esophagus

- Presenting author: Salih Samo, M.D., University of Kansas School of Medicine

- Date and Time: Monday, Oct. 12; 10:30 a.m.-4:15 p.m. Central time

- Key findings: According to gastroenterology society guidelines, patients diagnosed with non-dysplastic BE (NDBE) are generally recommended to undergo surveillance endoscopy every three to five years because they are considered at relatively low risk of progression. However, biopsy findings alone may not fully reflect a patient's underlying biological risk, and some patients may harbor advanced precancerous changes that cannot be detected through routine histopathologic assessment alone. In this case report, TissueCypher returned a high-risk result for a patient with NDBE, indicating a 62% probability of progression to HGD or EAC within five years. The result informed a risk-based management approach and led to a repeat endoscopy six months after the initial examination, at which previously missed prevalent HGD was identified. The patient subsequently underwent endoscopic eradication therapy (EET) with radiofrequency ablation (RFA). This case illustrates how TissueCypher may help identify elevated risk among patients with an NDBE diagnosis, helping clinicians identify patients who may benefit from earlier evaluation and intervention than would otherwise be recommended based on histology alone.

P5192: Real-World Impact of Tissue Systems Pathology Test on Barrett's Esophagus Management: A Multi-Center Cohort Study

- Presenting author: Shree Patel, M.D., Emory University School of Medicine

- Date and Time: Tuesday, Oct. 13; 10:30 a.m.-4 p.m. Central time

- Key findings: Histopathology and clinical factors alone may not fully identify which patients with BE are at elevated risk of progression to HGD/EAC. In the study, molecular risk stratification using TissueCypher was compared with the Progression in Barrett's (PIB) clinicopathologic-based risk stratification approach. There was only slight agreement between the two approaches (Cohen's κ = 0.04). TissueCypher classified 83% of patients as low risk and 17% as intermediate/high risk, whereas the PIB score classified 31% of patients as low risk and 69% as intermediate/high risk. Following TissueCypher testing, management recommendations were changed in a manner consistent with the test's risk classification for 96% of patients in this cohort, suggesting that the results informed clinical decision-making in this study population. Under guideline-informed management, most patients would have been recommended surveillance every three years using the PIB approach. However, guided by TissueCypher results, physicians recommended a longer five-year surveillance window for 38 patients and EET for eight, which included five patients with NDBE whose TissueCypher results indicated intermediate or high risk or progression despite having no dysplasia detected on their biopsy. These findings suggest that TissueCypher may provide additional risk information beyond clinicopathologic assessment to support more individualized surveillance and treatment recommendations.

P5296: The Tissue Systems Pathology Test Facilitated Early Intervention in a Histopathologically Complex Case of Barrett's Esophagus

- Presenting author: Shree Patel, M.D., Emory University School of Medicine

- Date and Time: Tuesday, Oct. 13; 10:30 a.m.-4 p.m. Central time

- Key findings: Conflicting biopsy results can make it difficult to determine the appropriate management strategy for patients with BE. In this case, a patient's biopsies were successively classified as NDBE, low-grade dysplasia (LGD) and indefinite for dysplasia (IND), creating uncertainty about the patient's risk and management plan. TissueCypher testing of the IND biopsy returned a high-risk result, indicating a 47% probability of progression to HGD or EAC within five years. The high-risk result prompted an interventional endoscopy with RFA two months after the endoscopy that yielded the IND diagnosis. Biopsies obtained during the procedure confirmed previously undetected HGD, consistent with the TissueCypher high-risk classification. Following RFA and subsequent cryotherapy, follow-up biopsies confirmed complete eradication of the patient's intestinal metaplasia. This case illustrates how TissueCypher may help reduce uncertainty for patients with inconclusive or discordant biopsy findings by providing objective risk information that supports timely intervention and individualized patient management.

TissueCypher Product Theater

- Date and Time: Tuesday, Oct. 13; 1:15-1:45 p.m. Central time

- Location: Product Theater Area (Booth 117)

- Castle will host a product theater titled, "Low-risk on histology. High-risk in reality: Johnny Walker's journey with Barrett's esophagus." During the session, TissueCypher patient ambassador Johnny Walker will join Mark Amorosino, M.D., gastroenterologist at Gastro Health, and David Forcione, M.D., advanced endoscopist at Baptist Health, to discuss how TissueCypher's molecular risk assessment provided additional insight beyond his NDBE diagnosis and informed treatment decisions that ultimately led to the detection of dysplasia.

For more information on TissueCypher, visit Castle at Booth 1706.

About TissueCypher Barrett's Esophagus Test

TissueCypher is a precision medicine test designed and extensively validated to predict a patient's personalized risk of progression from Barrett's esophagus (BE) to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). Indicated for patients with non-dysplastic BE, indefinite for dysplasia or with low-grade dysplasia, TissueCypher's five-year risk assessment is designed to help physicians tailor care to each patient's risk of developing HGD or EAC.

Backed by more than 17 peer-reviewed publications and studied in biopsies from more than 8,000 patients, TissueCypher has been shown to be the strongest independent predictor of progression compared with traditional histopathological risk assessment. Using an AI-derived spatialomics approach, the test identifies molecular signatures that often precede the development of dysplasia, which can enable earlier identification, treatment, and management of patients at increased risk of cancer. TissueCypher is designed to integrate seamlessly into routine endoscopic practice by analyzing standard esophageal pinch biopsies, delivering actionable insights without requiring additional procedures. Learn more at CastleBiosciences.com/TissueCypher.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.

We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X.

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections.

NEW YORK BLOOD CENTER ENTERPRISES APPOINTS MEGHAN DELANEY, DO, MPH, AS NEXT PRESIDENT & CHIEF EXECUTIVE OFFICER

Current President and CEO Christopher D. Hillyer, MD, to serve as Special Advisor to the Board of Trustees

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- The Board of Trustees of New York Blood Center Enterprises (NYBCe) has appointed Meghan Delaney, DO, MPH, as the organization's next President and Chief Executive Officer following an extensive national search. Dr. Delaney will assume the role on January 4, 2027, succeeding Christopher D. Hillyer, MD, who has led the organization since 2009.

Dr. Hillyer will transition to the role of Special Advisor to NYBCe's Board of Trustees. In this capacity, he will work closely with Dr. Delaney to support a smooth transition while continuing to provide strategic guidance to the Board and NYBCe leadership, ensuring the organization continues to benefit from his experience, expertise, and deep institutional knowledge.

During his 17-year tenure, Dr. Hillyer transformed NYBCe from a regional blood center and research institution into an internationally recognized life sciences enterprise serving 16 states and more than 550 hospitals. Under his leadership, NYBCe expanded the work of its Lindsley F. Kimball Research Institute (LFKRI) and advanced its capabilities in genomics, cellular therapies, and biomanufacturing. Key milestones included the FDA approval of HemaCord, the first FDA-licensed hematopoietic progenitor cell therapy product; the establishment of Comprehensive Cell Solutions; the founding of NYBC Ventures, a $50 million life sciences investment fund; and the opening of NYBCe's new Rye Master Campus, consolidating blood operations, research and cell therapy manufacturing under one roof.

"Dr. Hillyer's extraordinary contributions have left a lasting impact on NYBCe and the patients and communities we serve," said Marc Kramer, Chairman of NYBCe's Board of Trustees. "We are deeply grateful for his dedication and pleased that the organization will continue to benefit from his expertise and guidance. We are equally excited to welcome Dr. Delaney, whose clinical, scientific, and executive experience positions her well to guide NYBCe into the future."

"It has been a distinct honor and privilege to lead NYBCe for the better part of two decades. I am incredibly proud of what we have accomplished together and deeply grateful to the extraordinary people who make this organization what it is today," said Dr. Hillyer. "I look forward to welcoming Dr. Delaney and supporting her success as NYBCe continues to grow, innovate, and advance its lifesaving mission."

Dr. Delaney currently serves as Associate Chief Clinical Officer, Division Chief of Pathology and Laboratory Medicine, and Director of Transfusion Medicine at Children's National in Washington, D.C. She is also a Professor of Pathology and Pediatrics at the George Washington University School of Medicine and Health Sciences and serves on the Board of Directors of the Association for the Advancement of Blood & Biotherapies (AABB).

"I am honored to have been selected as the next President and CEO of New York Blood Center Enterprises and look forward to building on its exceptional history of service, scientific excellence, and innovation," said Dr. Delaney. "NYBCe plays a vital role in patient care, public health, scientific discovery, and the future of blood and cellular therapies. I am excited to work alongside its talented and dedicated employees, partners, and the communities we serve to embrace new opportunities and expand our impact for generations to come."

About New York Blood Center Enterprises (NYBCe)

Founded in 1964, New York Blood Center Enterprises (NYBCe) has provided more than 60 years of lifesaving research, innovation, and impact. NYBCe is one of the largest nonprofit blood centers, operating in 16 states and serving 75 million people. NYBCe operates Blood Bank of Delmarva, Community Blood Center of Greater Kansas City, Connecticut Blood Center, Memorial Blood Centers, Nebraska Community Blood Bank, New Jersey Blood Services, New York Blood Center, and Rhode Island Blood Center, delivering more than one million blood products to nearly 550 U.S. hospitals annually. NYBCe additionally delivers cellular therapies, specialty pharmacy, and medical services to 200+ research, academic, and biopharmaceutical organizations. NYBCe's Lindsley F. Kimball Research Institute is a leader in hematology and transfusion medicine research, dedicated to the study, prevention, treatment and cure of bloodborne and blood-related diseases. NYBCe is a vital community lifeline dedicated to helping patients and advancing global public health. To learn more, visit nybce.org. Connect with us on Facebook, X, Instagram, and LinkedIn.

SOURCE New York Blood Center Enterprises

Share this article

New Poetry Collection Explores Healing After Life's Hardest Moments

"Refine" offers readers an unfiltered look at the resilience of the human spirit

WILLIS, Texas, Oct. 12, 2026 /PRNewswire/ -- Author Katie Guilbault has released "Refine: An Anthology of Learning Life's Lessons the Hard Way," a collection of poetry and prose that explores grief, healing, motherhood, love, faith, mental health and self-discovery through reflections inspired by her personal experiences. In the book, Guilbault examines how life's greatest challenges can shape personal growth while encouraging readers to reflect on their own experiences with loss, resilience and transformation.

Organized as a series of poems and reflective essays, "Refine" follows Guilbault through childhood memories, changing family dynamics, motherhood, relationships and personal struggles. The collection addresses topics including mental health, generational trauma, divorce, body image, forgiveness and hope while documenting the experiences that have shaped her perspective over time.

"My goal is to give language to the parts of healing that people often experience in silence," Guilbault said. "I hope readers see pieces of their own story reflected and feel encouraged to continue refining who they are becoming."

Rather than presenting healing as a destination, Guilbault portrays it as an ongoing process marked by setbacks, reflection and personal growth. Each poem and prose piece builds on the last, creating a narrative that follows the author's journey from heartbreak and uncertainty to renewed purpose and hope. The collection encourages readers to reflect on their own lives while considering how even difficult experiences can become sources of wisdom and transformation.

"Healing is not linear, and every difficult season has shaped who I am today," Guilbault said. "I want readers to know that honest self-examination is necessary for transformation."

"Refine: An Anthology Of Learning Life's Lessons The Hard Way"

By Katie Guilbault

ISBN: 9798765268421 (softcover); 9798765268414 (hardcover); 9798765268407 (electronic)

Available on BalboaPress, Amazon and Barnes & Noble 

About the author

Katie Guilbault is a dreamer, a fighter, a mother and a writer. Drawing inspiration from surviving life with tomfoolery and therapeutic poetry. She is deeply spiritual and attributes her work to her purpose in life; creating community. To learn more, please visit https://www.balboapress.com/en/bookstore/bookdetails/872089-refine.

General Inquiries:

LAVIDGE – Phoenix

Maeve Larson

[email protected]

SOURCE Balboa Press

Share this article

Noble Corporation plc to announce third quarter 2026 results

HOUSTON, Oct. 12, 2026 /PRNewswire/ -- Noble Corporation plc ("Noble" or the "Company") (NYSE: NE) today announces plans to report financial results for the third quarter on Monday, October 26, 2026. The Company's earnings press release and accompanying earnings presentation will be available on Noble's website at www.noblecorp.com.

Noble will host a conference call related to its third quarter 2026 results on Tuesday, October 27, 2026, at 8:00 a.m. U.S. Central Time. Interested parties may dial (800) 715-9871 and refer to conference ID 4018911 approximately 15 minutes prior to the scheduled start time. A live webcast link will be available on the Investor Relations section of the Company's website, and a webcast replay will be accessible for a limited time following the scheduled call.

About Noble Corporation

Noble is a leading offshore drilling contractor for the oil and gas industry. The Company owns and operates one of the most modern, versatile, and technically advanced fleets in the offshore drilling industry. Noble and its predecessors have been engaged in the contract drilling of oil and gas wells since 1921. Noble performs, through its subsidiaries, contract drilling services with a fleet of offshore drilling units focused largely on ultra-deepwater and high specification jackup drilling opportunities in both established and emerging regions worldwide. For further information, visit www.noblecorp.com or email [email protected].

SOURCE Noble Corporation plc

Share this article

HOUSTON, Oct. 12, 2026 /PRNewswire/ -- Flotek Industries, Inc. ("Flotek" or the "Company") (NYSE: FTK) today announced the Company's schedule for releasing its third quarter 2026 financial and operating results.

The Company plans to issue its third quarter 2026 financial and operating results press release after market close on Tuesday, November 3, 2026, and host its earnings conference call on Wednesday, November 4, 2026, at 9:00 a.m. CT (10:00 a.m. ET). The press release will be posted on the Company's website at https://ir.flotekind.com/press-releases.

Participants may access the call through Flotek's website at https://ir.flotekind.com/events, by telephone toll free at 1-800-836-8184 (international toll: 1-646-357-8785), or by using the following link to access the webcast: https://app.webinar.net/KaD61d81pgX approximately five minutes prior to the start of the call. Following the conclusion of the conference call, a recording of the call will be available on the Company's website.

About Flotek Industries, Inc.

Flotek Industries, Inc. is a global technology-driven company that combines the synergy of proprietary technologies through near real-time data analytics and advanced chemistry to collaboratively address complex challenges for energy, industrial and infrastructure sector customers and help them optimize operations, enhance asset performance and maximize financial returns.

Leveraging a portfolio of more than 130 patents, over two decades of field and laboratory data, and a global presence in more than 59 countries, Flotek delivers innovative, data-driven solutions designed to create measurable value across the energy and infrastructure lifecycle.

Flotek is based in Houston, Texas and its common shares are traded on the New York Stock Exchange under the ticker symbol "FTK." For additional information, please visit www.flotekind.com.

SOURCE Flotek Industries, Inc.

Share this article